{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "NCT04745299",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "OtherEventStatsGroupId",
                  "OtherEventStatsNumAffected",
                  "OtherEventStatsNumAtRisk",
                  "OtherEventStatsNumEvents",
                  "OtherEventTerm",
                  "OtherOutcomeDescription",
                  "OtherOutcomeMeasure",
                  "OtherOutcomeTimeFrame",
                  "OutcomeAnalysisCILowerLimit",
                  "OutcomeAnalysisCILowerLimitComment",
                  "OutcomeAnalysisCINumSides",
                  "OutcomeAnalysisCIPctValue",
                  "OutcomeAnalysisCIUpperLimit",
                  "OutcomeAnalysisCIUpperLimitComment",
                  "OutcomeAnalysisDispersionType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OtherEventStatsGroupId": [],
                        "OtherEventStatsNumAffected": [],
                        "OtherEventStatsNumAtRisk": [],
                        "OtherEventStatsNumEvents": [],
                        "OtherEventTerm": [],
                        "OtherOutcomeDescription": [
                              "Change to SVC measured at 6, 12 months and 36 months",
                              "Change of Muscular strength which is measured by Hand Held Dynamometer (HHD)",
                              "Time to event for 36 months",
                              "Time to death means the period from randomization of a subject to physical death.\n\nThe comparison with the time to death between treatment groups and control group.",
                              "EQ-5D-5L is designed to measure health conditions and it consists of 5 questions relating to mobility, self-care, usual activities, pain/discomfort and anxiety/depression. 1~5 points are given for each question and a higher score means worse condition.\n\nChange of EQ-5D-5L from baseline to 6 month, 12 months, and 36 months.",
                              "ALSAQ-40 is designed to evaluate disease-specific health conditions of subjects with ALS/motor neural disease. It consists of 40 questions to evaluate 5 aspects of health conditions affected by the disease. Subjects are asked to think about the difficulties they may have experienced during the last 2 weeks. Subjects are asked to indicate the frequency of each event by selecting one of 5 options (0~4): never/rarely/sometimes/often/always or cannot do at all.",
                              "Tests on blood samples and cerebrospinal fluid samples for exploratory investigation of biological markers in plasma, blood and CSF.\n\nComparison of change before and after treatment.\n\nMeasurement cytokines : TGF-\u03b21, IL-10, IL-6, TNF-\u03b1, MCP-1, IL-8, IL-1RA, MIP-1\u03b2, RANTES and IP-10 etc.\nUnits of Measure: pg/mL\nComparative Analysis of how much each cytokine increases or decreases after treatment compared to before treatment."
                        ],
                        "OtherOutcomeMeasure": [
                              "Slow Vital Capacity (SVC)",
                              "Muscular strength",
                              "Time to event",
                              "Time to death",
                              "EuroQol Short Form (EQ-5D-5L)",
                              "Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40)",
                              "Biological test"
                        ],
                        "OtherOutcomeTimeFrame": [
                              "6 months, 12 months, 36 months",
                              "6 months, 12 months, 36 months",
                              "36 months",
                              "6 months, 12 months, 36 months",
                              "6 month, 12 months, 36 months",
                              "6 month, 12 months, 36 months",
                              "up to 12 months after administration"
                        ],
                        "OutcomeAnalysisCILowerLimit": [],
                        "OutcomeAnalysisCILowerLimitComment": [],
                        "OutcomeAnalysisCINumSides": [],
                        "OutcomeAnalysisCIPctValue": [],
                        "OutcomeAnalysisCIUpperLimit": [],
                        "OutcomeAnalysisCIUpperLimitComment": [],
                        "OutcomeAnalysisDispersionType": [],
                        "NCTId": [
                              "NCT04745299"
                        ]
                  }
            ]
      }
}